The lymphocyte transformation test and the macrophage migration inhibition test are quantitative methods invaluable for examination of @entity4345 (hereafter referred to as Be) effects on cell-mediated immunity. We recognized that the Be sensitizing ability was related to active as well as passive cell-mediated immunity in @entity19 subcutaneously injected with Be once a week over a 6-week period. Be also affects B cells, and it increases the amount of immunoglobulins in sera. In the study of immunological health surveys of Be workers in a @entity920 - @entity4345 casting factory, the serum complement titer tended to be lower in Be workers than in the controls. In @entity19 , injected with Be once a week over a 12-week period, serum complement titers decreased. Correlation coefficients of the experimental parameters showed a significant negative correlation between the complement titers and the prothrombin time or the coagulation time for factor VII, using @entity19 injected with 5 micrograms of Be. It was suggested that increases in the complement titers after Be administration may be induced by temporarily-activated plasma serin protease, which is a component of @entity1003 factor VII. The @entity8454 dehydratase and @entity10473 deaminase activities were significantly elevated in the pregnant untreated group, compared with the nonpregnant @entity19 (the control group). However, it was noted that these values in the pregnant @entity19 injected with 50 micrograms of Be were almost the same as the values of the controls. It suggests that Be suppressed the expected pregnancy-induced increase in hematopoietic function. There are at least two risk factors induced in the effects of @entity4345 on organisms-exposure to the metal and inheritance of the genetic marker. It is necessary to reduce exposure, to give preventive education and to carry out periodic health examinations for the prevention of disease induced by Be.

[Immunotoxicity of XXXX ].

@entity19 :: ('10090', 'Species') :: ['mice'] @entity4345 :: ('MESH:D001608', 'Chemical') :: ['beryllium'] @entity10473 :: ('MESH:D011162', 'Chemical') :: ['porphobilinogen'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['blood coagulation'] @entity920 :: ('MESH:D003300', 'Chemical') :: ['copper'] @entity8454 :: ('MESH:D000622', 'Chemical') :: ['delta-aminolevulinic acid']
@entity4345 :: (MESH:D001608,Chemical) :: ['beryllium']
